Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501704 · ClinicalTrials.gov registry record · Phase 2
ETHAN - ET for Male BC
A Phase 2 study of Hormone Receptor-Positive Breast Cancer and Male Breast Cancer, sponsored by Jose Pablo Leone.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT05501704: Recruiting Phase 2 study of Hormone Receptor-Positive Breast Cancer and Male Breast Cancer, sponsored by Jose Pablo Leone.
NCT05501704 is a Phase 2 study of Hormone Receptor-Positive Breast Cancer and Male Breast Cancer that is actively recruiting participants, run by Jose Pablo Leone. The registered enrollment target is 60 participants, below the 186-participant average among 23 other Hormone Receptor-Positive Breast Cancer trials with a reported enrollment target (68% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05501704, a Phase 2 study of Hormone Receptor-Positive Breast Cancer and Male Breast Cancer, is actively recruiting participants, sponsored by Jose Pablo Leone.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib
Primary Outcome
Ki-67 will be evaluated by ImmunoHistoChemistry (IHC) following consensus recommendations using imaging analysis methods.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Anastrozole
- DRUG Abemaciclib
- DRUG Degarelix
Study Locations (8)
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
- University of Pittsburgh Cancer Institute - Pittsburgh
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Tennessee
- Vanderbilt Cancer Center - Nashville
Texas
- M. D. Anderson Cancer Center at University of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-10-11 |
| Est. Completion | 2036-04-01 |
| Phase | Phase 2 |
What NCT05501704 shows while recruiting
NCT05501704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 186-participant average among 23 other Hormone Receptor-Positive Breast Cancer trials with a reported enrollment target (68% lower).
The record links to 3 conditions, with Hormone Receptor-Positive Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Tamoxifen is the first listed.
NCT05501704 lists 8 locations in 7 states (Pennsylvania, District of Columbia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05501704 about?
NCT05501704 is a clinical study titled "ETHAN - ET for Male BC". This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemacic...
What is the current status of trial NCT05501704?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-10-11. Estimated completion is 2036-04-01.
What conditions does trial NCT05501704 study?
This clinical trial studies the following conditions: Hormone Receptor-Positive Breast Cancer, Male Breast Cancer, Hormone Receptor-Negative Breast Carcinoma.
What interventions are being tested in trial NCT05501704?
The interventions under investigation include: Tamoxifen (DRUG), Anastrozole (DRUG), Abemaciclib (DRUG), Degarelix (DRUG).
Who is sponsoring clinical trial NCT05501704?
This trial is sponsored by Jose Pablo Leone, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05501704 being conducted?
This trial has 8 study locations across District of Columbia, Massachusetts, Minnesota, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hormone Receptor-Positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05501704's enrollment target sits among peer trials
60 18th of 23 higher than 5 of 23 other Hormone Receptor-Positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hormone Receptor-Positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI